Literature DB >> 25578878

Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions.

Jian Xu1,2, Zhen Shao1,3, Dan Li4, Huafeng Xie1, Woojin Kim1, Jialiang Huang1,5, Jordan E Taylor6, Luca Pinello5, Kimberly Glass5, Jacob D Jaffe6, Guo-Cheng Yuan5, Stuart H Orkin1,7.   

Abstract

Polycomb repressive complex 2 (PRC2) plays crucial roles in transcriptional regulation and stem cell development. However, the context-specific functions associated with alternative subunits remain largely unexplored. Here we show that the related enzymatic subunits EZH1 and EZH2 undergo an expression switch during blood cell development. An erythroid-specific enhancer mediates transcriptional activation of EZH1, and a switch from GATA2 to GATA1 controls the developmental EZH1/2 switch by differential association with EZH1 enhancers. We further examine the in vivo stoichiometry of the PRC2 complexes by quantitative proteomics and reveal the existence of an EZH1-SUZ12 subcomplex lacking EED. EZH1 together with SUZ12 form a non-canonical PRC2 complex, occupy active chromatin, and positively regulate gene expression. Loss of EZH2 expression leads to repositioning of EZH1 to EZH2 targets. Thus, the lineage- and developmental stage-specific regulation of PRC2 subunit composition leads to a switch from canonical silencing to non-canonical functions during blood stem cell specification.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25578878      PMCID: PMC4305004          DOI: 10.1016/j.molcel.2014.12.009

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  49 in total

Review 1.  Transcriptional regulation by Polycomb group proteins.

Authors:  Luciano Di Croce; Kristian Helin
Journal:  Nat Struct Mol Biol       Date:  2013-10       Impact factor: 15.369

2.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.

Authors:  Shuet Theng Lee; Zhimei Li; Zhenlong Wu; Meiyee Aau; Peiyong Guan; R K Murthy Karuturi; Yih Cherng Liou; Qiang Yu
Journal:  Mol Cell       Date:  2011-09-02       Impact factor: 17.970

3.  Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest.

Authors:  Isabel Hidalgo; Antonio Herrera-Merchan; Jose Manuel Ligos; Laura Carramolino; Javier Nuñez; Fernando Martinez; Orlando Dominguez; Miguel Torres; Susana Gonzalez
Journal:  Cell Stem Cell       Date:  2012-11-02       Impact factor: 24.633

4.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Authors:  Sarah K Knutson; Tim J Wigle; Natalie M Warholic; Christopher J Sneeringer; Christina J Allain; Christine R Klaus; Joelle D Sacks; Alejandra Raimondi; Christina R Majer; Jeffrey Song; Margaret Porter Scott; Lei Jin; Jesse J Smith; Edward J Olhava; Richard Chesworth; Mikel P Moyer; Victoria M Richon; Robert A Copeland; Heike Keilhack; Roy M Pollock; Kevin W Kuntz
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

5.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).

Authors:  Michael T McCabe; Alan P Graves; Gopinath Ganji; Elsie Diaz; Wendy S Halsey; Yong Jiang; Kimberly N Smitheman; Heidi M Ott; Melissa B Pappalardi; Kimberly E Allen; Stephanie B Chen; Anthony Della Pietra; Edward Dul; Ashley M Hughes; Seth A Gilbert; Sara H Thrall; Peter J Tummino; Ryan G Kruger; Martin Brandt; Benjamin Schwartz; Caretha L Creasy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

6.  Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation.

Authors:  Kairong Cui; Chongzhi Zang; Tae-Young Roh; Dustin E Schones; Richard W Childs; Weiqun Peng; Keji Zhao
Journal:  Cell Stem Cell       Date:  2009-01-09       Impact factor: 24.633

7.  An essential switch in subunit composition of a chromatin remodeling complex during neural development.

Authors:  Julie Lessard; Jiang I Wu; Jeffrey A Ranish; Mimi Wan; Monte M Winslow; Brett T Staahl; Hai Wu; Ruedi Aebersold; Isabella A Graef; Gerald R Crabtree
Journal:  Neuron       Date:  2007-07-19       Impact factor: 17.173

Review 8.  The Polycomb complex PRC2 and its mark in life.

Authors:  Raphaël Margueron; Danny Reinberg
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

9.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

10.  Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.

Authors:  Woojin Kim; Gregory H Bird; Tobias Neff; Guoji Guo; Marc A Kerenyi; Loren D Walensky; Stuart H Orkin
Journal:  Nat Chem Biol       Date:  2013-08-25       Impact factor: 15.040

View more
  61 in total

Review 1.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

2.  HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.

Authors:  Abhishek A Chakraborty; Eijiro Nakamura; Jun Qi; Amanda Creech; Jacob D Jaffe; Joshiawa Paulk; Jesse S Novak; Kshithija Nagulapalli; Samuel K McBrayer; Glenn S Cowley; Javier Pineda; Jiaxi Song; Yaoyu E Wang; Steven A Carr; David E Root; Sabina Signoretti; James E Bradner; William G Kaelin
Journal:  Sci Transl Med       Date:  2017-07-12       Impact factor: 17.956

3.  EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

Authors:  Yu Zhao; Liya Ding; Dejie Wang; Zhenqing Ye; Yundong He; Linlin Ma; Runzhi Zhu; Yunqian Pan; Qiang Wu; Kun Pang; Xiaonan Hou; Saravut J Weroha; Conghui Han; Roger Coleman; Ilsa Coleman; R Jeffery Karnes; Jun Zhang; Peter S Nelson; Liguo Wang; Haojie Huang
Journal:  EMBO J       Date:  2019-02-05       Impact factor: 11.598

Review 4.  The GATA factor revolution in hematology.

Authors:  Koichi R Katsumura; Emery H Bresnick
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

Review 5.  Polycomb and trithorax opposition in development and disease.

Authors:  Steven T Poynter; Cigall Kadoch
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2016-09-01       Impact factor: 5.814

6.  Repression by RB1 characterizes genes involved in the penultimate stage of erythroid development.

Authors:  Ji Zhang; Melanie R Loyd; Mindy S Randall; John J Morris; Jayesh G Shah; Paul A Ney
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation.

Authors:  Zhimin Gu; Yuxuan Liu; Feng Cai; McKenzie Patrick; Jakub Zmajkovic; Hui Cao; Yuannyu Zhang; Alpaslan Tasdogan; Mingyi Chen; Le Qi; Xin Liu; Kailong Li; Junhua Lyu; Kathryn E Dickerson; Weina Chen; Min Ni; Matthew E Merritt; Sean J Morrison; Radek C Skoda; Ralph J DeBerardinis; Jian Xu
Journal:  Cancer Discov       Date:  2019-06-12       Impact factor: 39.397

8.  A partially disordered region connects gene repression and activation functions of EZH2.

Authors:  Lianying Jiao; Murtada Shubbar; Xin Yang; Qi Zhang; Siming Chen; Qiong Wu; Zhe Chen; Josep Rizo; Xin Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

9.  Divergent Requirements for EZH1 in Heart Development Versus Regeneration.

Authors:  Shanshan Ai; Xianhong Yu; Yumei Li; Yong Peng; Chen Li; Yanzhu Yue; Ge Tao; Chuanyun Li; William T Pu; Aibin He
Journal:  Circ Res       Date:  2017-05-16       Impact factor: 17.367

10.  Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.

Authors:  Han Xu; Kexin Xu; Housheng H He; Chongzhi Zang; Chen-Hao Chen; Yiwen Chen; Qian Qin; Su Wang; Chenfei Wang; Shengen Hu; Fugen Li; Henry Long; Myles Brown; X Shirley Liu
Journal:  Mol Cancer Res       Date:  2015-12-09       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.